Compare Global Payments Inc (GPN) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global Payments Inc vs Recursion Pharmaceuticals Inc — how do they compare? Global Payments Inc trades at $81.99 (market cap $21.46B), while Recursion Pharmaceuticals Inc trades at $3.93 (market cap $2.14B). The key difference: Global Payments Inc is far larger — about 10× Recursion Pharmaceuticals Inc's market cap, and Global Payments Inc pays a 1.23% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global Payments Inc for 50 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| GPN | RXRX | |
|---|---|---|
Market Cap | $21.46B | $2.14B |
Volume | 1,482,600 | 30,789,535 |
Sector | Financials | Health |
52-Week High | $94.83 | $6.79 |
52-Week Low | $62.47 | $2.84 |
Typical Hold Time | 50 Days | 22 Days |
Enterprise Value | $39.60B | $1.66B |
Dividend Yield | 1.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Global Payments (GPN) trades at $81.08, down 0.87% on the day, with a bearish technical signal and mixed fundamentals. The stock has beaten earnings estimates for the last three quarters, but 2026 projections show a net loss. Analyst consensus is bullish with a $102.75 price target, though rising debt and competition pose risks.
The outlook hinges on successful integration of Genius and Worldpay platforms to drive growth, but investor caution is warranted due to negative profit margins forecasted for 2026 and high debt levels. Near-term price action is testing key support at $80.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
